Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy

• Published in: Cell death & disease Vol. 15; no. 1; p. 17
• Main Authors: Babamohamadi, Mehregan, Mohammadi, Nastaran, Faryadi, Elham, Haddadi, Maryam, Merati, Amirhossein, Ghobadinezhad, Farbod, Amirian, Roshanak, Izadi, Zhila, Hadjati, Jamshid
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.01.2024; Springer Nature B.V; Nature Publishing Group
• Subjects: 13/1; 13/21; 13/31; 13/51; 42/44; 631/250/251/1574; 631/67/1059/2325; Antibodies; Antibodies, Monoclonal; Antigens; Biochemistry; Biomedical and Life Sciences; Cancer; Cancer immunotherapy; Cell Biology; Cell Culture; Cell cycle; Cell proliferation; CTLA-4 Antigen; CTLA-4 protein; Cytotoxicity; Humans; Immune checkpoint; Immune Checkpoint Proteins; Immunology; Immunosuppressive agents; Immunotherapy; Life Sciences; Lymphocytes T; Metastases; Molecular weight; Monoclonal antibodies; Nanobodies; Neoplasms - therapy; Review; Review Article; Single-Domain Antibodies - therapeutic use; Tumors
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-023-06391-x

Cancer is one of the most common diseases and causes of death worldwide. Since common treatment approaches do not yield acceptable results in many patients, developing innovative strategies for effective treatment is necessary. Immunotherapy is one of the promising approaches that has been highly regarded for preventing tumor recurrence and new metastases. Meanwhile, inhibiting immune checkpoints is one of the most attractive methods of cancer immunotherapy. Cytotoxic T lymphocyte-associated protein-4 (CTLA-4) is an essential immune molecule that plays a vital role in cell cycle modulation, regulation of T cell proliferation, and cytokine production. This molecule is classically expressed by stimulated T cells. Inhibition of overexpression of immune checkpoints such as CTLA-4 receptors has been confirmed as an effective strategy. In cancer immunotherapy, immune checkpoint-blocking drugs can be enhanced with nanobodies that target immune checkpoint molecules. Nanobodies are derived from the variable domain of heavy antibody chains. These small protein fragments have evolved entirely without a light chain and can be used as a powerful tool in imaging and treating diseases with their unique structure. They have a low molecular weight, which makes them smaller than conventional antibodies while still being able to bind to specific antigens. In addition to low molecular weight, specific binding to targets, resistance to temperature, pH, and enzymes, high ability to penetrate tumor tissues, and low toxicity make nanobodies an ideal approach to overcome the disadvantages of monoclonal antibody-based immunotherapy. In this article, while reviewing the cellular and molecular functions of CTLA-4, the structure and mechanisms of nanobodies’ activity, and their delivery methods, we will explain the advantages and challenges of using nanobodies, emphasizing immunotherapy treatments based on anti-CTLA-4 nanobodies.